标签归档：cdk

CDK4/6-IN-5

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK4/6-IN-5 

CDK4/6-IN-5 是一种有效的 CDK4 和 CDK6 抑制剂，对 CDK4/Cyclin D1 和 CDK6/Cyclin D3 的 Ki 值为 0.2 和 4.4 nM。

CDK4/6-IN-5

CDK4/6-IN-5 Chemical Structure

CAS No. : 2380321-50-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK4/6-IN-5 is a potent CDK4 and CDK6 inhibitor with Kis of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively[1]. (from patent WO2019207463A1 example A93).

体外研究
(In Vitro)

The CDK4 and CDK6 cell-based IC50s of CDK4/6-IN-5 in JEKO-1 and MV4-1 1 cells are 23.8 and 61.4 nM, respectively[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

527.01

Formula

C22H28ClFN6O4S
CAS 号

2380321-50-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ping Chen, et al. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors. WO2019207463A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK4/6-IN-6

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK4/6-IN-6 

CDK4/6-IN-6 (example A94) 是一种有效的 CDK4/CDK6 抑制剂，对CDK4/Cyclin D1 和 CDK6/Cyclin D3 的 Ki 值为 0.6 nM 和 13.9 nM。

CDK4/6-IN-6

CDK4/6-IN-6 Chemical Structure

CAS No. : 2380321-51-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK4/6-IN-6 (example A94) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively[1].

IC50 & Target[1]

Cdk4/cyclin D1

0.6 nM (Ki)

cdk6/cyclin D3

13.9 nM (Ki)

体外研究
(In Vitro)

CDK4/6-IN-6 (example A94) has IC50s of 38.5 nM and 144.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3 using phospho-Rb S795 ELISA assays in JEKO-1 and MV4-1 1 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

463.93

Formula

C22H27ClFN5O3
CAS 号

2380321-51-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ping Chen, et al. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors. WO2019207463A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK4/6-IN-6

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK4/6-IN-6 

CDK4/6-IN-6 (example A94) 是一种有效的 CDK4/CDK6 抑制剂，对CDK4/Cyclin D1 和 CDK6/Cyclin D3 的 Ki 值为 0.6 nM 和 13.9 nM。

CDK4/6-IN-6

CDK4/6-IN-6 Chemical Structure

CAS No. : 2380321-51-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK4/6-IN-6 (example A94) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively[1].

IC50 & Target[1]

Cdk4/cyclin D1

0.6 nM (Ki)

cdk6/cyclin D3

13.9 nM (Ki)

体外研究
(In Vitro)

CDK4/6-IN-6 (example A94) has IC50s of 38.5 nM and 144.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3 using phospho-Rb S795 ELISA assays in JEKO-1 and MV4-1 1 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

463.93

Formula

C22H27ClFN5O3
CAS 号

2380321-51-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ping Chen, et al. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors. WO2019207463A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK4/6-IN-6

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK4/6-IN-6 

CDK4/6-IN-6 (example A94) 是一种有效的 CDK4/CDK6 抑制剂，对CDK4/Cyclin D1 和 CDK6/Cyclin D3 的 Ki 值为 0.6 nM 和 13.9 nM。

CDK4/6-IN-6

CDK4/6-IN-6 Chemical Structure

CAS No. : 2380321-51-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK4/6-IN-6 (example A94) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively[1].

IC50 & Target[1]

Cdk4/cyclin D1

0.6 nM (Ki)

cdk6/cyclin D3

13.9 nM (Ki)

体外研究
(In Vitro)

CDK4/6-IN-6 (example A94) has IC50s of 38.5 nM and 144.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3 using phospho-Rb S795 ELISA assays in JEKO-1 and MV4-1 1 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

463.93

Formula

C22H27ClFN5O3
CAS 号

2380321-51-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ping Chen, et al. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors. WO2019207463A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK7-IN-13

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK7-IN-13 

CDK7-IN-13 是一种有效的 CDK7 抑制剂。CDK7-IN-13 是一种嘧啶基衍生化合物。CDK7-IN-13 具有研究多种癌症的潜力，尤其是转录失调的癌症 (摘自专利 CN114249712A，化合物 1)。

CDK7-IN-13

CDK7-IN-13 Chemical Structure

CAS No. : 2765676-20-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK7-IN-13 is a potent inhibitor of CDK7. CDK7-IN-13 is a pyrimidinyl derivative compound. CDK7-IN-13 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1)[1].

分子量

452.50

Formula

C20H23F3N6OS
CAS 号

2765676-20-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Guanpeng Qiu, et al. Pyrimidinyl derivatives, method for the production thereof and use thereof. Patent CN114249712A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK7-IN-15

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK7-IN-15 

CDK7-IN-15 是一种有效的 CDK7 抑制剂。CDK7-IN-15 是一种嘧啶基衍生化合物。CDK7-IN-15 具有研究多种癌症的潜力，尤其是转录失调的癌症 (摘自专利 CN114249712A，化合物 8)。

CDK7-IN-15

CDK7-IN-15 Chemical Structure

CAS No. : 2765676-02-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK7-IN-15 is a potent inhibitor of CDK7. CDK7-IN-15 is a pyrimidinyl derivative compound. CDK7-IN-15 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 8)[1].

分子量

484.51

Formula

C21H24F4N6OS
CAS 号

2765676-02-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Guanpeng Qiu, et al. Pyrimidinyl derivatives, method for the production thereof and use thereof. Patent CN114249712A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK7-IN-17

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK7-IN-17 

CDK7-IN-17 是一种有效的 CDK7 抑制剂。CDK7-IN-17 是一种嘧啶基衍生化合物。CDK7-IN-17 具有研究多种癌症的潜力，尤其是转录失调的癌症 (摘自专利 CN114249712A，化合物 11)。

CDK7-IN-17

CDK7-IN-17 Chemical Structure

CAS No. : 2765676-60-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK7-IN-17 is a potent inhibitor of CDK7. CDK7-IN-17 is a pyrimidinyl derivative compound. CDK7-IN-17 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1)[1].

分子量

502.47

Formula

C24H26F3N6OP
CAS 号

2765676-60-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Guanpeng Qiu, et al. Pyrimidinyl derivatives, method for the production thereof and use thereof. Patent CN114249712A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK7-IN-18

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK7-IN-18 

CDK7-IN-18 是一种有效的 CDK7 抑制剂。CDK7-IN-18 是一种嘧啶基衍生化合物。CDK7-IN-18 具有研究多种癌症的潜力，尤其是转录失调的癌症 (摘自专利 CN114249712A，化合物 15)。

CDK7-IN-18

CDK7-IN-18 Chemical Structure

CAS No. : 2765676-81-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK7-IN-18 is a potent inhibitor of CDK7. CDK7-IN-18 is a pyrimidinyl derivative compound. CDK7-IN-18 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 15)[1].

分子量

491.53

Formula

C22H24F3N7OS
CAS 号

2765676-81-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Guanpeng Qiu, et al. Pyrimidinyl derivatives, method for the production thereof and use thereof. Patent CN114249712A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK7-IN-14

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK7-IN-14 

CDK7-IN-14 是一种有效的 CDK7 抑制剂。CDK7-IN-14 是一种嘧啶基衍生化合物。CDK7-IN-14 具有研究多种癌症的潜力，尤其是转录失调的癌症 (摘自专利 CN114249712A，化合物 3)。

CDK7-IN-14

CDK7-IN-14 Chemical Structure

CAS No. : 2765676-49-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK7-IN-14 is a potent inhibitor of CDK7. CDK7-IN-14 is a pyrimidinyl derivative compound. CDK7-IN-14 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 3)[1].

分子量

476.43

Formula

C22H24F3N6OP
CAS 号

2765676-49-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Guanpeng Qiu, et al. Pyrimidinyl derivatives, method for the production thereof and use thereof. Patent CN114249712A.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK9-IN-12

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK9-IN-12 

CDK9-IN-12 显示了最佳的 CDK9 抑制活性，IC50 值为 5.41 nM。

CDK9-IN-12

CDK9-IN-12 Chemical Structure

CAS No. : 1942843-54-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM.

IC50 & Target

CDK9/cyclinT1

5.41 nM (IC50)

分子量

378.85

Formula

C21H19ClN4O
CAS 号

1942843-54-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Han X, et al. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021 Oct 14;64(19):14647-14663.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK9-IN-12

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK9-IN-12 

CDK9-IN-12 显示了最佳的 CDK9 抑制活性，IC50 值为 5.41 nM。

CDK9-IN-12

CDK9-IN-12 Chemical Structure

CAS No. : 1942843-54-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM.

IC50 & Target

CDK9/cyclinT1

5.41 nM (IC50)

分子量

378.85

Formula

C21H19ClN4O
CAS 号

1942843-54-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Han X, et al. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021 Oct 14;64(19):14647-14663.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK9-IN-12

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK9-IN-12 

CDK9-IN-12 显示了最佳的 CDK9 抑制活性，IC50 值为 5.41 nM。

CDK9-IN-12

CDK9-IN-12 Chemical Structure

CAS No. : 1942843-54-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC50 value of 5.41 nM.

IC50 & Target

CDK9/cyclinT1

5.41 nM (IC50)

分子量

378.85

Formula

C21H19ClN4O
CAS 号

1942843-54-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Han X, et al. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2021 Oct 14;64(19):14647-14663.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK2-IN-7

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK2-IN-7 

CDK2-IN-7 是一种治疗癌症的 CDK2 抑制剂（IC50 < 50 nM）。

CDK2-IN-7

CDK2-IN-7 Chemical Structure

CAS No. : 2498658-13-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK2-IN-7 is a CDK2 inhibitor for treating cancer (IC50 < 50 nM).

IC50 & Target

CDK2/cyclinE

50 nM (IC50)

分子量

498.60

Formula

C24H30N6O4S
CAS 号

2498658-13-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Sabnis RW. Sulfonylamide Compounds as CDK2 Inhibitors for Treating Cancer. ACS Med Chem Lett. 2021 Sep 13;12(10):1528-1529.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK2-IN-7

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK2-IN-7 

CDK2-IN-7 是一种治疗癌症的 CDK2 抑制剂（IC50 < 50 nM）。

CDK2-IN-7

CDK2-IN-7 Chemical Structure

CAS No. : 2498658-13-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK2-IN-7 is a CDK2 inhibitor for treating cancer (IC50 < 50 nM).

IC50 & Target

CDK2/cyclinE

50 nM (IC50)

分子量

498.60

Formula

C24H30N6O4S
CAS 号

2498658-13-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Sabnis RW. Sulfonylamide Compounds as CDK2 Inhibitors for Treating Cancer. ACS Med Chem Lett. 2021 Sep 13;12(10):1528-1529.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK2-IN-7

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK2-IN-7 

CDK2-IN-7 是一种治疗癌症的 CDK2 抑制剂（IC50 < 50 nM）。

CDK2-IN-7

CDK2-IN-7 Chemical Structure

CAS No. : 2498658-13-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK2-IN-7 is a CDK2 inhibitor for treating cancer (IC50 < 50 nM).

IC50 & Target

CDK2/cyclinE

50 nM (IC50)

分子量

498.60

Formula

C24H30N6O4S
CAS 号

2498658-13-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Sabnis RW. Sulfonylamide Compounds as CDK2 Inhibitors for Treating Cancer. ACS Med Chem Lett. 2021 Sep 13;12(10):1528-1529.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CDK/HDAC-IN-2

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK/HDAC-IN-2 

CDK/HDAC-IN-2 是一种有效的 HDAC/CDK 双重抑制剂，对于 HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, IC50 分别为 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM。CDK/HDAC-IN-2 显示出优异的抗增殖活性。CDK/HDAC-IN-2 诱导细胞凋亡 (apoptosis) 和细胞周期停滞在 G2/M 期。CDK/HDAC-IN-2 显示出强大的抗肿瘤功效。

CDK/HDAC-IN-2

CDK/HDAC-IN-2 Chemical Structure

CAS No. : 2580938-58-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK/HDAC-IN-2 is a potent HDAC/CDK dual inhibitor with IC50 of 6.4, 0.25, 45, >1000, 8.63, 0.30, >1000 nM for HDAC1, HDAC2, HDAC3, HDAC6,8, CDK1, CDK2, CDK4,6,7, respectively. CDK/HDAC-IN-2 shows excellent antiproliferative activities. CDK/HDAC-IN-2 induces apoptosis and cell cycle arrest at G2/M phase. CDK/HDAC-IN-2 shows potent antitumor efficacy[1].

IC50 & Target[1]

HDAC1

6.4 nM (IC50)

HDAC2

0.25 nM (IC50)

HDAC3

45 nM (IC50)

HDAC6

>1000 nM (IC50)

HDAC8

>1000 nM (IC50)

CDK1

8.63 nM (IC50)

CDK2

0.30 μM (IC50)

CDK4

>1000 nM (IC50)

CDK6

>1000 nM (IC50)

CDK7

>1000 nM (IC50)

体外研究
(In Vitro)

CDK/HDAC-IN-2 (compound 7c) shows antiproliferative activity with IC50s of 0.71, 1.20, 1.83, 4.19, 7.76, 4.47 µM for HCT116, A375, Hela, H460, SMMC7721, NIH 3T3 cells, respectively[1].
CDK/HDAC-IN-2 (24 h) shows anti-migration ability in A375 and H460 cells[1].
CDK/HDAC-IN-2 (0.5, 1, 2 µM) induces apoptosis and cell cycle arrest at G2/M phase[1].
CDK/HDAC-IN-2 accelerates intracellular ROS accumulation, leading to cancer cell death[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line: A375, HCT116, H460, Hela cells
Concentration: 0.5, 1, 2 µM
Incubation Time: 24 h
Result: Induced cell cycle arrest at G2/M phase.

Apoptosis Analysis[1]

Cell Line: A375, HCT116, H460, Hela cells
Concentration: 0.5, 1, 2 µM
Incubation Time: 48 h
Result: Induced cell apoptosis with the apoptosis rates of A375, HCT116 cells of 97.22%, 60.6%, respectively.

体内研究
(In Vivo)

CDK/HDAC-IN-2 (12.5, 25 mg/kg; IP; once daily for 21 days) shows antitumor efficacy in the HCT116 xenograft model (TGI= 51.0%)[1].
Pharmacokinetic Parameters of CDK/HDAC-IN-2 in ICR male mice[1].

compound 7c
Dose (mg/kg) 20
administration i.p.
t1/2 (h) 2.61
Tmax (h) 2.00
Cmax (h) 7570
AUC0-∞ (ng h/mL) 30700
MRT0-∞ (ng h/mL) 3.31
F (%) 63.6

ICR male mice; 20 mg/kg, i.p.[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ICR male mice[1]
Dosage: 20 mg/kg
Administration: IP
Result: Showed good Pharmacokinetic parameters with bioavailability of F= 63.6%.
Animal Model: 5-6 weeks, BALB/c female mice (HCT116 xenograft nude mice models)[1]
Dosage: 12.5, 25 mg/kg
Administration: IP, once daily for 21 days
Result: Effectively inhibited the growth of HCT116 xenograft tumors tumor growth inhibitions (TGI) at 12.5 and 25 mg/kg of 37.0% and 51.0%, respectively.

分子量

523.37

Formula

C25H20Cl2N6O3
CAS 号

2580938-58-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Cheng C, et al. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. Eur J Med Chem. 2020 Mar 1;189:112073.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PROTAC CDK9 degrader-4

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PROTAC CDK9 degrader-4 

PROTAC CDK9 degrader-4 是一种高效、靶向转录调控的 CDK9 降解物。

PROTAC CDK9 degrader-4

PROTAC CDK9 degrader-4 Chemical Structure

CAS No. : 2411021-01-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PROTAC CDK9 degrader-4 is a highly potent and efficacious CDK9 degrader for targeting transcription regulation.

分子量

792.97

Formula

C43H56N10O5
CAS 号

2411021-01-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wei D, et al. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem. 2021 Oct 14;64(19):14822-14847.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PROTAC CDK9 ligand-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PROTAC CDK9 ligand-1 

PROTAC CDK9 ligand-1 是一种可用于合成 PROTAC 的 CDK9 配体。

PROTAC CDK9 ligand-1

PROTAC CDK9 ligand-1 Chemical Structure

CAS No. : 2411021-95-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PROTAC CDK9 ligand-1 is a CDK9 ligand that can be used in the synthesis of PROTACs.

分子量

368.48

Formula

C20H28N6O
CAS 号

2411021-95-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wei D, et al. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem. 2021 Oct 14;64(19):14822-14847.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PROTAC CDK9 degrader-4

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PROTAC CDK9 degrader-4 

PROTAC CDK9 degrader-4 是一种高效、靶向转录调控的 CDK9 降解物。

PROTAC CDK9 degrader-4

PROTAC CDK9 degrader-4 Chemical Structure

CAS No. : 2411021-01-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PROTAC CDK9 degrader-4 is a highly potent and efficacious CDK9 degrader for targeting transcription regulation.

分子量

792.97

Formula

C43H56N10O5
CAS 号

2411021-01-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wei D, et al. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem. 2021 Oct 14;64(19):14822-14847.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PROTAC CDK9 ligand-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PROTAC CDK9 ligand-1 

PROTAC CDK9 ligand-1 是一种可用于合成 PROTAC 的 CDK9 配体。

PROTAC CDK9 ligand-1

PROTAC CDK9 ligand-1 Chemical Structure

CAS No. : 2411021-95-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PROTAC CDK9 ligand-1 is a CDK9 ligand that can be used in the synthesis of PROTACs.

分子量

368.48

Formula

C20H28N6O
CAS 号

2411021-95-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wei D, et al. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem. 2021 Oct 14;64(19):14822-14847.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务